 SAN DIEGO, CA ACCESSWIRE March 31, 2021 Nascent Biotech, Inc. OTCQB:NBIO Nascent Biotech, Nascent, or the Company, a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Companys landmark Phase I trial to evaluate Pritumumab PTB as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Patient enrollment remains open, and the trial continues to recruit new patients for participation. 